{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T12:05:03Z","timestamp":1791288303760,"version":"4.3.0"},"reference-count":202,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2014,9,1]],"date-time":"2014-09-01T00:00:00Z","timestamp":1409529600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"National Institute of Health","award":["R37EB000244"],"award-info":[{"award-number":["R37EB000244"]}]},{"name":"National Institute of Health","award":["K99EB016690"],"award-info":[{"award-number":["K99EB016690"]}]},{"name":"National Institute of Health","award":["R01EB016101"],"award-info":[{"award-number":["R01EB016101"]}]},{"name":"Institute for Soldier Nanotechnologies","award":["W911NF-13-D-0001"],"award-info":[{"award-number":["W911NF-13-D-0001"]}]},{"DOI":"10.13039\/501100001348","name":"Agency of Science, Technology and Research","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001348","id-type":"DOI","asserted-by":"crossref"}]},{"name":"National Science Foundation"},{"name":"Koch Institute Bridge"},{"name":"Koch Institute Core"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2014,9]]},"DOI":"10.1016\/j.jconrel.2014.04.049","type":"journal-article","created":{"date-parts":[[2014,5,4]],"date-time":"2014-05-04T21:17:37Z","timestamp":1399238257000},"page":"157-171","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":49,"special_numbering":"C","title":["Single compartment drug delivery"],"prefix":"10.1016","volume":"190","author":[{"given":"Michael J.","family":"Cima","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heejin","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Daniel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura M.","family":"Tanenbaum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aikaterini","family":"Mantzavinou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin C.","family":"Spencer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qunya","family":"Ong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay C.","family":"Sy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"John","family":"Santini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carl M.","family":"Schoellhammer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Blankschtein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert S.","family":"Langer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2014.04.049_bb0005","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1016\/j.addr.2004.02.014","article-title":"Nanoparticle and targeted systems for cancer therapy","volume":"56","author":"Brannon-Peppas","year":"2004","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2014.04.049_bb0010","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJM200103153441101","article-title":"Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2","volume":"344","author":"Slamon","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jconrel.2014.04.049_bb0015","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1177\/1947601913488598","article-title":"Survival of HER2-positive breast cancer cells: receptor signaling to apoptotic control centers","volume":"4","author":"Fink","year":"2013","journal-title":"Genes Cancer"},{"key":"10.1016\/j.jconrel.2014.04.049_bb0020","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1158\/1078-0432.CCR-09-2546","article-title":"Low level HER2 overexpression is associated with rapid tumor cell proliferation and poor prognosis in prostate cancer","volume":"16","author":"Minner","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jconrel.2014.04.049_bb0025","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.ctrv.2008.09.003","article-title":"HER2-targeted therapy in breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors","volume":"35","author":"Nielsen","year":"2009","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.jconrel.2014.04.049_bb0030","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/ncponc0509","article-title":"Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer","volume":"3","author":"Nahta","year":"2006","journal-title":"Nat. Clin. Pract. Oncol."},{"key":"10.1016\/j.jconrel.2014.04.049_bb0035","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1158\/1078-0432.CCR-08-3087","article-title":"HER-2, notch, and breast cancer stem cells: targeting an axis of evil","volume":"15","author":"Korkaya","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jconrel.2014.04.049_bb0040","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1096\/fasebj.12.12.1063","article-title":"Cyclooxygenase in biology and disease","volume":"12","author":"Dubois","year":"1998","journal-title":"FASEB J."},{"key":"10.1016\/j.jconrel.2014.04.049_bb0045","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/0166-2236(95)93890-A","article-title":"Cytokines and the nervous system II: actions and mechanisms of action","volume":"18","author":"Rothwell","year":"1995","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.jconrel.2014.04.049_bb0050","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/35068632","article-title":"Inflammatory response: pathway across the blood\u2013brain barrier","volume":"410","author":"Ek","year":"2001","journal-title":"Nature"},{"key":"10.1016\/j.jconrel.2014.04.049_bb0055","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1093\/jnci\/93.8.597","article-title":"Methods to improve efficacy of intravesical mitomycin C: results of a randomized phase III trial","volume":"93","author":"Au","year":"2001","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.jconrel.2014.04.049_bb0060","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1152\/physiol.00036.2010","article-title":"Regulation of smooth muscle contraction by the epithelium: role of prostaglandins","volume":"26","author":"Ruan","year":"2011","journal-title":"Physiology"},{"key":"10.1016\/j.jconrel.2014.04.049_bb0065","doi-asserted-by":"crossref","first-page":"F463","DOI":"10.1152\/ajprenal.00575.2012","article-title":"Prostaglandin E2 promotes cellular recovery from established nephrotoxic serum nephritis in mice, prosurvival, and regenerative effects on glomerular cells","volume":"304","author":"Kvirkvelia","year":"2013","journal-title":"Am. J. Physiol. Ren. Physiol."},{"key":"10.1016\/j.jconrel.2014.04.049_bb0070","doi-asserted-by":"crossref","first-page":"16987","DOI":"10.1073\/pnas.1313185110","article-title":"Prostaglandin E2 deficiency causes a phenotype of aspirin sensitivity that depends on platelets and cysteinyl leukotrienes","volume":"110","author":"Liu","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jconrel.2014.04.049_bb0075","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1161\/ATVBAHA.110.216374","article-title":"The prostaglandin E2 receptor EP4 is expressed by human platelets and potently inhibits platelet aggregation and thrombus formation","volume":"30","author":"Philipose","year":"2010","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.jconrel.2014.04.049_bb0080","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1097\/MOG.0b013e32834b3fcb","article-title":"Gastrointestinal defense mechanisms","volume":"27","author":"Palileo","year":"2011","journal-title":"Curr. Opin. Gastroenterol."},{"key":"10.1016\/j.jconrel.2014.04.049_bb0085","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S0049-3848(03)00380-3","article-title":"Variants of cyclooxygenase-1 and their roles in medicine","volume":"110","author":"Simmons","year":"2003","journal-title":"Thromb. Res."},{"key":"10.1016\/j.jconrel.2014.04.049_bb0090","doi-asserted-by":"crossref","first-page":"12013","DOI":"10.1073\/pnas.91.25.12013","article-title":"Pharmacological and biochemical demonstration of the role of cyclooxygenase 2 in inflammation and pain","volume":"91","author":"Seibert","year":"1994","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jconrel.2014.04.049_bb0095","first-page":"2029","article-title":"Celecoxib exhibits the greatest potency amongst cyclooxygenase (COX) inhibitors for growth inhibition of COX-2-negative hematopoietic and epithelial cell lines","volume":"62","author":"Waskewich","year":"2002","journal-title":"Cancer Res."},{"key":"10.1016\/j.jconrel.2014.04.049_bb0100","first-page":"1876","article-title":"Upper gastrointestinal tolerability of celecoxib, a COX-2 specific inhibitor, compared to naproxen and placebo","volume":"27","author":"Bensen","year":"2000","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.jconrel.2014.04.049_bb0105","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1111\/j.1572-0241.2000.02194.x","article-title":"Reduced risk of upper gastrointestinal ulcer complications with celecoxib, a novel COX-2 inhibitor","volume":"95","author":"Goldstein","year":"2000","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.jconrel.2014.04.049_bb0110","first-page":"25","article-title":"Significant upper gastrointestinal events associated with conventional NSAID versus celecoxib","volume":"60","author":"Goldstein","year":"2000","journal-title":"J. Rheumatol. Suppl."},{"key":"10.1016\/j.jconrel.2014.04.049_bb0115","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1177\/014107680609900315","article-title":"Risk of cardiovascular events and celecoxib: a systematic review and meta-analysis","volume":"99","author":"Caldwell","year":"2006","journal-title":"J. R. Soc. Med."},{"key":"10.1016\/j.jconrel.2014.04.049_bb0120","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1001\/archinte.165.9.978","article-title":"Risk of hospitalization for myocardial infarction among users of rofecoxib, celecoxib, and other NSAIDs: a population-based case\u2013control study","volume":"165","author":"Johnsen","year":"2005","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.jconrel.2014.04.049_bb0125","doi-asserted-by":"crossref","first-page":"157","DOI":"10.7326\/0003-4819-142-3-200502010-00005","article-title":"Patients exposed to rofecoxib and celecoxib have different odds of nonfatal myocardial infarction","volume":"142","author":"Kimmel","year":"2005","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.jconrel.2014.04.049_bb0130","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1056\/NEJM200108093450607","article-title":"The coxibs, selective inhibitors of cyclooxygenase-2","volume":"345","author":"FitzGerald","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jconrel.2014.04.049_bb0135","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S0090-4295(99)00492-6","article-title":"Muscarinic receptor antagonists in the treatment of overactive bladder","volume":"55","author":"Chapple","year":"2000","journal-title":"Urology"},{"key":"10.1016\/j.jconrel.2014.04.049_bb0140","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1111\/j.1532-5415.2005.00537.x","article-title":"Antimuscarinic drugs for overactive bladder and their potential effects on cognitive function in older patients","volume":"53","author":"Kay","year":"2005","journal-title":"J. Am. Geriatr. Soc."},{"key":"10.1016\/j.jconrel.2014.04.049_bb0145","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/S1474-4422(03)00622-7","article-title":"Antimuscarinics for treatment of overactive bladder","volume":"3","author":"Andersson","year":"2004","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.jconrel.2014.04.049_bb0150","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1007\/s00192-011-1411-6","article-title":"Antimuscarinics for the treatment of overactive bladder: understanding the role of muscarinic subtype selectivity","volume":"22","author":"Glavind","year":"2011","journal-title":"Int. Urogynecol. J."},{"key":"10.1016\/j.jconrel.2014.04.049_bb0155","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/0163-7258(93)90027-B","article-title":"Muscarinic receptors\u2014characterization, coupling and function","volume":"58","author":"Caulfield","year":"1993","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.jconrel.2014.04.049_bb0160","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1038\/35065604","article-title":"Mice lacking the M3 muscarinic acetylcholine receptor are hypophagic and lean","volume":"410","author":"Yamada","year":"2001","journal-title":"Nature"},{"key":"10.1016\/j.jconrel.2014.04.049_bb0165","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/S0090-4295(02)01803-4","article-title":"Muscarinic receptor subtypes and management of the overactive bladder","volume":"60","author":"Chapple","year":"2002","journal-title":"Urology"},{"key":"10.1016\/j.jconrel.2014.04.049_bb0170","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.eururo.2005.02.024","article-title":"The effects of antimuscarinic treatments in overactive bladder: a systematic review and meta-analysis","volume":"48","author":"Chapple","year":"2005","journal-title":"Eur. Urol."},{"key":"10.1016\/j.jconrel.2014.04.049_bb0175","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.eururo.2008.06.047","article-title":"The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis","volume":"54","author":"Chapple","year":"2008","journal-title":"Eur. Urol."},{"key":"10.1016\/j.jconrel.2014.04.049_bb0180","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1124\/jpet.104.067140","article-title":"Functional selectivity of muscarinic receptor antagonists for inhibition of M3-mediated phosphoinositide responses in guinea pig urinary bladder and submandibular salivary gland","volume":"310","author":"Nelson","year":"2004","journal-title":"Pharmacol. Exp. Ther."},{"key":"10.1016\/j.jconrel.2014.04.049_bb0185","series-title":"Antimuscarinic Drugs for Overactive Bladder","author":"Gomelsky","year":"2012"},{"key":"10.1016\/j.jconrel.2014.04.049_bb0190","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1007\/s11884-010-0078-z","article-title":"Topical pharmacotherapy for overactive bladder","volume":"6","author":"Chung","year":"2011","journal-title":"Curr. Bladder Dysfunct. Rep."},{"key":"10.1016\/j.jconrel.2014.04.049_bb0195","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1016\/j.biomaterials.2010.12.020","article-title":"Intracranial microcapsule drug delivery device for the treatment of an experimental gliosarcoma model","volume":"32","author":"Scott","year":"2011","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2014.04.049_bb0200","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1111\/j.1464-410X.2010.09317.x","article-title":"Botulinum toxin for the lower urinary tract","volume":"105","author":"Chuang","year":"2010","journal-title":"BJU Int."},{"key":"10.1016\/j.jconrel.2014.04.049_bb0205","article-title":"An updated systematic review and statistical comparison of standardised mean outcomes for the use of botulinum toxin in the management of lower urinary tract disorders","author":"Mangera","year":"2013","journal-title":"Eur. Urol."},{"key":"10.1016\/j.jconrel.2014.04.049_bb0210","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1111\/iju.12106","article-title":"Editorial comment from Dr Funahashi to intravesical drug delivery for dysfunctional bladder","volume":"20","author":"Funahashi","year":"2013","journal-title":"Int. J. Urol."},{"key":"10.1016\/j.jconrel.2014.04.049_bb0215","doi-asserted-by":"crossref","first-page":"10258","DOI":"10.1016\/j.biomaterials.2013.09.027","article-title":"A magnetic chitosan hydrogel for sustained and prolonged delivery of Bacillus Calmette\u2013Guerin in the treatment of bladder cancer","volume":"34","author":"Zhang","year":"2013","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2014.04.049_bb0220","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1046\/j.1464-410X.2003.04124.x","article-title":"A novel device for reconstituting and delivering intravesical chemotherapy","volume":"91","author":"McLarty","year":"2003","journal-title":"BJU Int."},{"key":"10.1016\/j.jconrel.2014.04.049_bb0225","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1111\/j.1464-410X.2006.05965.x","article-title":"Immediate administration of intravesical mitomycin C after tumour resection for superficial bladder cancer","volume":"97","author":"Mostafid","year":"2006","journal-title":"BJU Int."},{"key":"10.1016\/j.jconrel.2014.04.049_bb0230","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1016\/j.juro.2013.05.011","article-title":"Pharmacokinetics of intravesical versus oral oxybutynin in healthy adults: results of an open label, randomized, prospective clinical study","volume":"190","author":"Krause","year":"2013","journal-title":"J. Urol."},{"key":"10.1016\/j.jconrel.2014.04.049_bb0235","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.jconrel.2010.08.031","article-title":"Intravesical drug delivery: challenges, current status, opportunities and novel strategies","volume":"148","author":"GuhaSarkar","year":"2010","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2014.04.049_bb0240","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1111\/iju.12085","article-title":"Intravesical drug delivery for dysfunctional bladder","volume":"20","author":"Hsu","year":"2013","journal-title":"Int. J. Urol."},{"key":"10.1016\/j.jconrel.2014.04.049_bb0245","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1021\/mp060001j","article-title":"Recent advances in intravesical drug\/gene delivery","volume":"3","author":"Tyagi","year":"2006","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jconrel.2014.04.049_bb0250","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/j.eururo.2006.08.025","article-title":"New frontiers in intravesical therapies and drug delivery","volume":"50","author":"Giannantoni","year":"2006","journal-title":"Eur. Urol."},{"key":"10.1016\/j.jconrel.2014.04.049_bb0255","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.ucl.2006.06.012","article-title":"Local drug delivery to bladder using technology innovations","volume":"33","author":"Tyagi","year":"2006","journal-title":"Urol. Clin. N. Am."},{"key":"10.1016\/j.jconrel.2014.04.049_bb0260","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/S1470-2045(11)70190-5","article-title":"Electromotive instillation of mitomycin immediately before transurethral resection for patients with primary urothelial non-muscle invasive bladder cancer: a randomised controlled trial","volume":"12","author":"Di Stasi","year":"2011","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.jconrel.2014.04.049_bb0265","doi-asserted-by":"crossref","first-page":"262313","DOI":"10.1155\/2013\/262313","article-title":"Hyperthermia as adjunct to intravesical chemotherapy for bladder cancer","volume":"2013","author":"Owusu","year":"2013","journal-title":"Biomed. Res. Int."},{"key":"10.1016\/j.jconrel.2014.04.049_bb0270","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1111\/j.1464-410X.2010.09654.x","article-title":"Long-term outcomes of a randomized controlled trial comparing thermochemotherapy with mitomycin-C alone as adjuvant treatment for non-muscle-invasive bladder cancer (NMIBC)","volume":"107","author":"Colombo","year":"2011","journal-title":"BJU Int."},{"key":"10.1016\/j.jconrel.2014.04.049_bb0275","doi-asserted-by":"crossref","DOI":"10.1007\/s00280-014-2381-4","article-title":"Intravesical thermo-chemotherapy based on conductive heat: a first pharmacokinetic study with Mitomycin C in superficial transitional cell carcinoma patients","author":"Milla","year":"2014","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.jconrel.2014.04.049_bb0280","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1016\/j.juro.2009.06.024","article-title":"Intravesical liposome versus oral pentosan polysulfate for interstitial cystitis\/painful bladder syndrome","volume":"182","author":"Chuang","year":"2009","journal-title":"J. Urol."},{"key":"10.1016\/j.jconrel.2014.04.049_bb0285","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.kjms.2011.06.002","article-title":"Safety and dose flexibility clinical evaluation of intravesical liposome in patients with interstitial cystitis or painful bladder syndrome","volume":"27","author":"Lee","year":"2011","journal-title":"Kaohsiung J. Med. Sci."},{"key":"10.1016\/j.jconrel.2014.04.049_bb0290","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/601653","article-title":"Intravesical liposome and antisense treatment for detrusor overactivity and interstitial cystitis\/painful bladder syndrome","volume":"2014","author":"Tyagi","year":"2014","journal-title":"ISRN Pharmacol."},{"key":"10.1016\/j.jconrel.2014.04.049_bb0295","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1089\/hum.2011.013","article-title":"Intravesical interleukin-15 gene therapy in an orthotopic bladder cancer model","volume":"22","author":"Matsumoto","year":"2011","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.jconrel.2014.04.049_bb0300","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1016\/j.juro.2012.10.123","article-title":"Development of potential orphan drug therapy of intravesical liposomal tacrolimus for hemorrhagic cystitis due to increased local drug exposure","volume":"189","author":"Nirmal","year":"2013","journal-title":"J. Urol."},{"key":"10.1016\/j.jconrel.2014.04.049_bb0305","doi-asserted-by":"crossref","first-page":"6425","DOI":"10.1039\/c2nr31592k","article-title":"Delivering instilled hydrophobic drug to the bladder by a cationic nanoparticle and thermo-sensitive hydrogel composite system","volume":"4","author":"Men","year":"2012","journal-title":"Nanoscale"},{"key":"10.1016\/j.jconrel.2014.04.049_bb0310","first-page":"2145","article-title":"Intravesical chemo-immunotherapy in non muscle invasive bladder cancer","volume":"17","author":"Leopardo","year":"2013","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"10.1016\/j.jconrel.2014.04.049_bb0315","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/s00280-003-0597-9","article-title":"Intravesical administration of doxorubicin to swine bladder using magnetically targeted carriers","volume":"51","author":"Leakakos","year":"2003","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.jconrel.2014.04.049_bb0320","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1021\/bm301868f","article-title":"Progress in targeting tumor cells by using drug-magnetic nanoparticles conjugate","volume":"14","author":"Nowicka","year":"2013","journal-title":"Biomacromolecules"},{"key":"10.1016\/j.jconrel.2014.04.049_bb0325","doi-asserted-by":"crossref","DOI":"10.1002\/jps.23854","article-title":"In situ floating hydrogel for intravesical delivery of adriamycin without blocking urinary tract","author":"Lin","year":"2014","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2014.04.049_bb0330","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.jconrel.2010.05.036","article-title":"Zero-order controlled release of ciprofloxacin\u2013HCl from a reservoir-based, bioresorbable and elastomeric device","volume":"146","author":"Tobias","year":"2010","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2014.04.049_bb0335","series-title":"Biodegradable implant for the intravesical therapy of the overactive bladder syndrome","first-page":"2951","article-title":"Development of an active agent carrying","author":"Michaeli","year":"2009"},{"key":"10.1016\/j.jconrel.2014.04.049_bb0340","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.jconrel.2013.05.018","article-title":"Lipid-based intravesical drug delivery systems with controlled release of trospium chloride for the urinary bladder","volume":"170","author":"Haupt","year":"2013","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2014.04.049_bb0345","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0090-4295(00)01020-7","article-title":"Advancements in pharmacologic management of the overactive bladder","volume":"56","author":"Dmochowski","year":"2000","journal-title":"Urology"},{"issue":"Suppl. 1","key":"10.1016\/j.jconrel.2014.04.049_bb0350","first-page":"S27","article-title":"Future trends in the treatment of urinary incontinence","volume":"3","author":"Chancellor","year":"2001","journal-title":"Rev. Urol."},{"key":"10.1016\/j.jconrel.2014.04.049_bb0355","first-page":"1","article-title":"The future of bladder control\u2014intravesical drug delivery, a pinch of pepper, and gene therapy","volume":"4","author":"Fraser","year":"2002","journal-title":"Rev. Urol."},{"key":"10.1016\/j.jconrel.2014.04.049_bb0360","first-page":"82","article-title":"I-oxy","volume":"3","author":"Oxybutynin intravesical\u2014situs","year":"2002","journal-title":"Drugs R&D"},{"key":"10.1016\/j.jconrel.2014.04.049_bb0365","series-title":"Drug Delivery Device for Bladder Disorders","author":"Lee","year":"2009"},{"key":"10.1016\/j.jconrel.2014.04.049_bb0370","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.jconrel.2010.10.016","article-title":"An intravesical device for the sustained delivery of lidocaine to the bladder","volume":"149","author":"Lee","year":"2011","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2014.04.049_bb0375","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3003804","article-title":"Continuous intravesical lidocaine treatment for interstitial cystitis\/bladder pain syndrome: safety and efficacy of a new drug delivery device","volume":"4","author":"Nickel","year":"2012","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.jconrel.2014.04.049_bb0380","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1146\/annurev-chembioeng-061010-114120","article-title":"Microsystem technologies for medical applications","volume":"2","author":"Cima","year":"2011","journal-title":"Annu. Rev. Chem. Biomol. Eng."},{"key":"10.1016\/j.jconrel.2014.04.049_bb0385","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1016\/j.addr.2012.02.003","article-title":"Osmotic micropumps for drug delivery","volume":"64","author":"Herrlich","year":"2012","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2014.04.049_bb0390","first-page":"546","article-title":"Pain: novel lidocaine delivery device for chronic interstitial cystitis","volume":"9","author":"Payton","year":"2012","journal-title":"Nat. Rev. Urol."},{"key":"10.1016\/j.jconrel.2014.04.049_bb0395","doi-asserted-by":"crossref","first-page":"F433","DOI":"10.1152\/ajprenal.00313.2004","article-title":"The transport barrier in intraperitoneal therapy","volume":"288","author":"Flessner","year":"2005","journal-title":"Am. J. Physiol. Ren. Physiol."},{"key":"10.1016\/j.jconrel.2014.04.049_bb0400","first-page":"1","article-title":"Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer","volume":"62","author":"Dedrick","year":"1978","journal-title":"Cancer Treat. Rep."},{"issue":"Suppl. 1","key":"10.1016\/j.jconrel.2014.04.049_bb0405","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/j.1525-1438.2007.01099.x","article-title":"Pharmacologic principles of intraperitoneal chemotherapy for the treatment of ovarian cancer","volume":"18","author":"Howell","year":"2008","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.jconrel.2014.04.049_bb0410","doi-asserted-by":"crossref","first-page":"203","DOI":"10.2165\/11598890-000000000-00000","article-title":"Pharmacokinetics and pharmacodynamics of intraperitoneal cancer chemotherapeutics","volume":"51","author":"Hasovits","year":"2012","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.jconrel.2014.04.049_bb0415","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/S1470-2045(03)01074-X","article-title":"Intraperitoneal antineoplastic drug delivery: rationale and results","volume":"4","author":"Markman","year":"2003","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.jconrel.2014.04.049_bb0420","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.2353\/ajpath.2010.100105","article-title":"Ovarian cancer development and metastasis","volume":"177","author":"Lengyel","year":"2010","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.jconrel.2014.04.049_bb0425","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1056\/NEJM199612263352603","article-title":"Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer","volume":"335","author":"Alberts","year":"1996","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jconrel.2014.04.049_bb0430","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1200\/JCO.2001.19.4.1001","volume":"19","author":"Markman","year":"2001","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jconrel.2014.04.049_bb0435","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1056\/NEJMoa052985","article-title":"Intraperitoneal cisplatin and paclitaxel in ovarian cancer","volume":"354","author":"Armstrong","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jconrel.2014.04.049_bb0440","doi-asserted-by":"crossref","first-page":"690","DOI":"10.6004\/jnccn.2013.0203","article-title":"New issues in systemic therapy for ovarian cancer","volume":"11","author":"Armstrong","year":"2013","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"10.1016\/j.jconrel.2014.04.049_bb0445","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1177\/1758834010361333","article-title":"Practical considerations in ovarian cancer chemotherapy","volume":"2","author":"Cristea","year":"2010","journal-title":"Ther. Adv. Med. Oncol."},{"key":"10.1016\/j.jconrel.2014.04.049_bb0450","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1038\/nrc1611","article-title":"Ovarian cancer metastasis: integrating insights from disparate model organisms","volume":"5","author":"Naora","year":"2005","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.jconrel.2014.04.049_bb0455","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.2217\/fon.10.100","article-title":"Intraperitoneal therapy for peritoneal cancer","volume":"6","author":"Lu","year":"2010","journal-title":"Future Oncol."},{"key":"10.1016\/j.jconrel.2014.04.049_bb0460","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ygyno.2005.11.013","article-title":"Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: a Gynecologic Oncology Group Study","volume":"100","author":"Walker","year":"2006","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.jconrel.2014.04.049_bb0465","doi-asserted-by":"crossref","first-page":"S260","DOI":"10.1016\/j.fertnstert.2008.08.057","article-title":"Treatment of pelvic pain associated with endometriosis","volume":"90","author":"M. Practice Committee of American Society for Reproductive","year":"2008","journal-title":"Fertil. Steril."},{"key":"10.1016\/j.jconrel.2014.04.049_bb0470","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1093\/neuonc\/2.1.45","article-title":"The blood\u2013brain and blood\u2013tumor barriers: a review of strategies for increasing drug delivery","volume":"2","author":"Groothuis","year":"2000","journal-title":"Neuro-Oncology"},{"key":"10.1016\/j.jconrel.2014.04.049_bb0475","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1097\/00146965-200312000-00001","article-title":"A review of the cognitive and behavioral sequelae of Parkinson's disease: relationship to frontostriatal circuitry","volume":"16","author":"Zgaljardic","year":"2003","journal-title":"Cogn. Behav. Neurol."},{"key":"10.1016\/j.jconrel.2014.04.049_bb0480","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1001\/archpsyc.58.7.631","article-title":"Regional brain metabolic changes in patients with major depression treated with either paroxetine or interpersonal therapy: preliminary findings","volume":"58","author":"Brody","year":"2001","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.jconrel.2014.04.049_bb0485","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1001\/archneur.64.1.20","article-title":"Circuits and circuit disorders of the basal ganglia","volume":"64","author":"DeLong","year":"2007","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.jconrel.2014.04.049_bb0490","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1176\/appi.ajp.2009.08091354","article-title":"Functional disturbances within frontostriatal circuits across multiple childhood psychopathologies","volume":"166","author":"Marsh","year":"2009","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jconrel.2014.04.049_bb0495","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1038\/nn.3088","article-title":"Localized microstimulation of primate pregenual cingulate cortex induces negative decision-making","volume":"15","author":"Amemori","year":"2012","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.jconrel.2014.04.049_bb0500","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/1357-4310(96)88720-X","article-title":"Transporting therapeutics across the blood\u2013brain barrier","volume":"2","author":"Abbott","year":"1996","journal-title":"Mol. Med. Today"},{"key":"10.1016\/j.jconrel.2014.04.049_bb0505","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/nrd725","article-title":"Drug and gene targeting to the brain with molecular Trojan horses","volume":"1","author":"Pardridge","year":"2002","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jconrel.2014.04.049_bb0510","first-page":"5590","article-title":"The effect of an amino acid-lowering diet on the rate of melphalan entry into brain and xenotransplanted glioma","volume":"52","author":"Groothuis","year":"1992","journal-title":"Cancer Res."},{"key":"10.1016\/j.jconrel.2014.04.049_bb0515","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.ijpharm.2005.03.031","article-title":"Colloidal carriers and blood\u2013brain barrier (BBB) translocation: a way to deliver drugs to the brain?","volume":"298","author":"Garcia-Garcia","year":"2005","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2014.04.049_bb0520","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1054\/bjoc.2000.1459","article-title":"High intratumoural accumulation of stealth liposomal doxorubicin (Caelyx) in glioblastomas and in metastatic brain tumours","volume":"83","author":"Koukourakis","year":"2000","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.jconrel.2014.04.049_bb0525","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1002\/1097-0142(20011001)92:7<1936::AID-CNCR1712>3.0.CO;2-H","article-title":"Long-term stabilization in patients with malignant glioma after treatment with liposomal doxorubicin","volume":"92","author":"Fabel","year":"2001","journal-title":"Cancer"},{"key":"10.1016\/j.jconrel.2014.04.049_bb0530","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1126\/science.180.4089.971","article-title":"Osmotic opening of the blood\u2013brain barrier in the monkey without associated neurological deficits","volume":"180","author":"Rapoport","year":"1973","journal-title":"Science"},{"key":"10.1016\/j.jconrel.2014.04.049_bb0535","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1602\/neurorx.2.4.541","article-title":"Medicinal chemical properties of successful central nervous system drugs","volume":"2","author":"Pajouhesh","year":"2005","journal-title":"NeuroRx"},{"key":"10.1016\/j.jconrel.2014.04.049_bb0540","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S1359-6446(03)02961-1","article-title":"Prediction of blood\u2013brain barrier penetration: are we missing the point?","volume":"9","author":"Martin","year":"2004","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.jconrel.2014.04.049_bb0545","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1080\/00498250802499459","article-title":"Toward an improved prediction of human in vivo brain penetration","volume":"38","author":"Summerfield","year":"2008","journal-title":"Xenobiotica"},{"key":"10.1016\/j.jconrel.2014.04.049_bb0550","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1080\/00498250701570285","article-title":"Challenges for blood\u2013brain barrier (BBB) screening","volume":"37","author":"Jeffrey","year":"2007","journal-title":"Xenobiotica"},{"key":"10.1016\/j.jconrel.2014.04.049_bb0555","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/S1359-6446(02)02332-2","article-title":"Barriers to remember: brain-targeting chemical delivery systems and Alzheimer's disease","volume":"7","author":"Bodor","year":"2002","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.jconrel.2014.04.049_bb0560","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0169-409X(98)00090-8","article-title":"Recent advances in the brain targeting of neuropharmaceuticals by chemical delivery systems","volume":"36","author":"Bodor","year":"1999","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2014.04.049_bb0565","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/nrd3028","article-title":"Membrane transporters in drug development","volume":"9","author":"Giacomini","year":"2010","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jconrel.2014.04.049_bb0570","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1021\/bc800148t","article-title":"Re-engineering biopharmaceuticals for delivery to brain with molecular Trojan horses","volume":"19","author":"Pardridge","year":"2008","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.jconrel.2014.04.049_bb0575","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1038\/nm.3407","article-title":"Development, maintenance and disruption of the blood\u2013brain barrier","volume":"19","author":"Obermeier","year":"2013","journal-title":"Nat. Med."},{"key":"10.1016\/j.jconrel.2014.04.049_bb0580","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1002\/jbio.200900095","article-title":"Site-specific opening of the blood\u2013brain barrier","volume":"3","author":"Madsen","year":"2010","journal-title":"J. Biophotonics"},{"key":"10.1016\/j.jconrel.2014.04.049_bb0585","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1002\/cncr.23624","article-title":"Invasive tumor cells and prognosis in a selected population of patients with glioblastoma multiforme","volume":"113","author":"Mangiola","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.jconrel.2014.04.049_bb0590","doi-asserted-by":"crossref","first-page":"189","DOI":"10.3747\/co.2007.147","article-title":"Gliadel wafers in the treatment of malignant glioma: a systematic review","volume":"14","author":"Perry","year":"2007","journal-title":"Curr. Oncol."},{"key":"10.1016\/j.jconrel.2014.04.049_bb0595","first-page":"329","article-title":"Interstitial chemotherapy of the 9L gliosarcoma: controlled release polymers for drug delivery in the brain","volume":"53","author":"Tamargo","year":"1993","journal-title":"Cancer Res."},{"key":"10.1016\/j.jconrel.2014.04.049_bb0600","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1152\/physrev.00027.2007","article-title":"Diffusion in brain extracellular space","volume":"88","author":"Sykova","year":"2008","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.jconrel.2014.04.049_bb0605","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1023\/A:1016083113123","article-title":"Chemotherapeutic drugs released from polymers: distribution of 1,3-bis(2-chloroethyl)-1-nitrosourea in the rat brain","volume":"13","author":"Fung","year":"1996","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2014.04.049_bb0610","doi-asserted-by":"crossref","first-page":"5768","DOI":"10.1016\/j.biomaterials.2012.04.048","article-title":"Intracranial MEMS based temozolomide delivery in a 9L rat gliosarcoma model","volume":"33","author":"Masi","year":"2012","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2014.04.049_bb0615","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1016\/0009-2509(91)80036-X","article-title":"Drugs released from polymers: diffusion and elimination in brain tissue","volume":"46","author":"Saltzman","year":"1991","journal-title":"Chem. Eng. Sci."},{"key":"10.1016\/j.jconrel.2014.04.049_bb0620","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.1073\/pnas.91.6.2076","article-title":"Convection-enhanced delivery of macromolecules in the brain","volume":"91","author":"Bobo","year":"1994","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jconrel.2014.04.049_bb0625","doi-asserted-by":"crossref","first-page":"117","DOI":"10.2217\/fon.09.135","article-title":"Future of convection-enhanced delivery in the treatment of brain tumors","volume":"6","author":"Bidros","year":"2010","journal-title":"Future Oncol."},{"key":"10.1016\/j.jconrel.2014.04.049_bb0630","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1586\/ern.09.99","article-title":"Convection-enhanced delivery for the treatment of brain tumors","volume":"9","author":"Debinski","year":"2009","journal-title":"Expert. Rev. Neurother."},{"key":"10.1016\/j.jconrel.2014.04.049_bb0635","doi-asserted-by":"crossref","first-page":"867","DOI":"10.3171\/JNS\/2008\/109\/11\/0867","article-title":"Convection-enhanced delivery of polyethylene glycol-coated liposomal doxorubicin: characterization and efficacy in rat intracranial glioma models","volume":"109","author":"Kikuchi","year":"2008","journal-title":"J. Neurosurg."},{"key":"10.1016\/j.jconrel.2014.04.049_bb0640","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s00381-008-0684-7","article-title":"Local chemotherapy in the rat brainstem with multiple catheters: a feasibility study","volume":"25","author":"Thomale","year":"2009","journal-title":"Childs Nerv. Syst."},{"key":"10.1016\/j.jconrel.2014.04.049_bb0645","doi-asserted-by":"crossref","first-page":"E12","DOI":"10.3171\/foc.2006.20.4.7","article-title":"Convection-enhanced delivery of therapeutics for brain disease, and its optimization","volume":"20","author":"Raghavan","year":"2006","journal-title":"Neurosurg. Focus."},{"key":"10.1016\/j.jconrel.2014.04.049_bb0650","doi-asserted-by":"crossref","first-page":"E8","DOI":"10.3171\/2009.4.FOCUS0983","article-title":"In vivo performance of a microelectrode neural probe with integrated drug delivery","volume":"27","author":"Rohatgi","year":"2009","journal-title":"Neurosurg. Focus."},{"key":"10.1016\/j.jconrel.2014.04.049_bb0655","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s11060-004-1497-5","article-title":"Intratumoral delivery of mitoxantrone in association with 90-Y radioimmunotherapy (RIT) in recurrent glioblastoma","volume":"72","author":"Boiardi","year":"2005","journal-title":"J. Neuro-Oncol."},{"key":"10.1016\/j.jconrel.2014.04.049_bb0660","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1097\/00000421-200202000-00013","article-title":"Intratumoral doxorubicin in patients with malignant brain gliomas","volume":"25","author":"Voulgaris","year":"2002","journal-title":"Am. J. Clin. Oncol."},{"key":"10.1016\/j.jconrel.2014.04.049_bb0665","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s100720050009","article-title":"Locally delivered chemotherapy and repeated surgery can improve survival in glioblastoma patients","volume":"20","author":"Boiardi","year":"1999","journal-title":"Ital. J. Neurol. Sci."},{"key":"10.1016\/j.jconrel.2014.04.049_bb0670","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1007\/s002590050549","article-title":"Role of nuclear medicine in the treatment of malignant gliomas: the locoregional radioimmunotherapy approach","volume":"27","author":"Riva","year":"2000","journal-title":"Eur. J. Nucl. Med."},{"key":"10.1016\/j.jconrel.2014.04.049_bb0675","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1023\/A:1020291229317","article-title":"A phase I trial of continuously infused intratumoral bleomycin for the treatment of recurrent glioblastoma multiforme","volume":"60","author":"Patchell","year":"2002","journal-title":"J. Neuro-Oncol."},{"key":"10.1016\/j.jconrel.2014.04.049_bb0680","doi-asserted-by":"crossref","first-page":"35","DOI":"10.2165\/0023210-200923010-00003","article-title":"Getting into the brain: approaches to enhance brain drug delivery","volume":"23","author":"Patel","year":"2009","journal-title":"CNS Drugs"},{"key":"10.1016\/j.jconrel.2014.04.049_bb0685","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.expneurol.2006.07.015","article-title":"Point source concentration of GDNF may explain failure of phase II clinical trial","volume":"202","author":"Salvatore","year":"2006","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.jconrel.2014.04.049_bb0690","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1126\/science.1241224","article-title":"Sleep drives metabolite clearance from the adult brain","volume":"342","author":"Xie","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.jconrel.2014.04.049_bb0695","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3003748","article-title":"A paravascular pathway facilitates CSF flow through the brain parenchyma and the clearance of interstitial solutes, including amyloid beta","volume":"4","author":"Iliff","year":"2012","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.jconrel.2014.04.049_bb0700","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/1743-8454-5-10","article-title":"Multiplicity of cerebrospinal fluid functions: new challenges in health and disease","volume":"5","author":"Johanson","year":"2008","journal-title":"Cerebrospinal Fluid Res."},{"key":"10.1016\/j.jconrel.2014.04.049_bb0705","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1016\/j.addr.2004.07.011","article-title":"Principles and applicability of CSF sampling for the assessment of CNS drug delivery and pharmacodynamics","volume":"56","author":"Shen","year":"2004","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2014.04.049_bb0710","first-page":"1","article-title":"Direct, quantitative, and noninvasive imaging of the transport of active agents through intact brain with positron emission tomography","author":"Sirianni","year":"2013","journal-title":"Mol. Imaging Biol."},{"key":"10.1016\/j.jconrel.2014.04.049_bb0715","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1038\/nature12808","article-title":"Transcranial amelioration of inflammation and cell death after brain injury","volume":"505","author":"Roth","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.jconrel.2014.04.049_bb0720","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/nrd1414","article-title":"Targeted therapy for brain tumours","volume":"3","author":"Lesniak","year":"2004","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jconrel.2014.04.049_bb0725","doi-asserted-by":"crossref","first-page":"345","DOI":"10.5483\/BMBRep.2008.41.5.345","article-title":"Blood\u2013neural barrier: its diversity and coordinated cell-to-cell communication","volume":"41","author":"Choi","year":"2008","journal-title":"BMB Rep."},{"key":"10.1016\/j.jconrel.2014.04.049_bb0730","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1038\/nri1224","article-title":"Ocular immune privilege: therapeutic opportunities from an experiment of nature","volume":"3","author":"Streilein","year":"2003","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.jconrel.2014.04.049_bb0735","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1159\/000209665","article-title":"Novel drug delivery systems for retinal diseases. A review","volume":"41","author":"Lee","year":"2009","journal-title":"Ophthalmic Res."},{"key":"10.1016\/j.jconrel.2014.04.049_bb0740","doi-asserted-by":"crossref","first-page":"5403","DOI":"10.1167\/iovs.10-5392","article-title":"Ophthalmic drug delivery systems for the treatment of retinal diseases: basic research to clinical applications","volume":"51","author":"Edelhauser","year":"2010","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.jconrel.2014.04.049_bb0745","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1002\/jps.21987","article-title":"A review of implantable intravitreal drug delivery technologies for the treatment of posterior segment eye diseases","volume":"99","author":"Choonara","year":"2010","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2014.04.049_bb0750","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1208\/s12248-010-9183-3","article-title":"Ocular drug delivery","volume":"12","author":"Gaudana","year":"2010","journal-title":"AAPS J."},{"key":"10.1016\/j.jconrel.2014.04.049_bb0755","unstructured":"Medicare Part B Physician\/Supplier BESS Data for Calendar Year 2012, in."},{"key":"10.1016\/j.jconrel.2014.04.049_bb0760","doi-asserted-by":"crossref","first-page":"4433","DOI":"10.1167\/iovs.12-9872","article-title":"Targeted administration into the suprachoroidal space using a microneedle for drug delivery to the posterior segment of the eye","volume":"53","author":"Patel","year":"2012","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.jconrel.2014.04.049_bb0765","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1167\/iovs.13-11747","article-title":"Treatment of acute posterior uveitis in a porcine model by injection of triamcinolone acetonide into the suprachoroidal space using microneedles","volume":"54","author":"Gilger","year":"2013","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.jconrel.2014.04.049_bb0770","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1007\/s10544-009-9313-9","article-title":"A passive MEMS drug delivery pump for treatment of ocular diseases","volume":"11","author":"Lo","year":"2009","journal-title":"Biomed. Microdevices"},{"key":"10.1016\/j.jconrel.2014.04.049_bb0775","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.sna.2007.06.034","article-title":"An electrochemical intraocular drug delivery device","volume":"143","author":"Li","year":"2008","journal-title":"Sensors Actuators A Phys."},{"key":"10.1016\/j.jconrel.2014.04.049_bb0780","doi-asserted-by":"crossref","first-page":"2744","DOI":"10.1039\/c1lc20134d","article-title":"On-demand controlled release of docetaxel from a battery-less MEMS drug delivery device","volume":"11","author":"Pirmoradi","year":"2011","journal-title":"Lab Chip"},{"key":"10.1016\/j.jconrel.2014.04.049_bb0785","article-title":"Topical delivery of ocular therapeutics: carrier systems and physical methods","author":"Souza","year":"2013","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.jconrel.2014.04.049_bb0790","first-page":"32","article-title":"New developments in the transscleral delivery of ophthalmic agents","author":"Csaky","year":"2007","journal-title":"Retin. Today"},{"key":"10.1016\/j.jconrel.2014.04.049_bb0795","first-page":"633","article-title":"Ocular iontophoresis of EGP-437 (dexamethasone phosphate) in dry eye patients: results of a randomized clinical trial","volume":"5","author":"Patane","year":"2011","journal-title":"Clin. Ophthalmol."},{"key":"10.1016\/j.jconrel.2014.04.049_bb0800","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.ultrasmedbio.2012.11.010","article-title":"Ultrasound-enhanced delivery of antibiotics and anti-inflammatory drugs into the eye","volume":"39","author":"Nabili","year":"2013","journal-title":"Ultrasound Med. Biol."},{"key":"10.1016\/j.jconrel.2014.04.049_bb0805","doi-asserted-by":"crossref","first-page":"4358","DOI":"10.1167\/iovs.13-11978","article-title":"Ultrasound-mediated transscleral delivery of macromolecules to the posterior segment of rabbit eye in vivo","volume":"54","author":"Suen","year":"2013","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.jconrel.2014.04.049_bb0810","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/j.visres.2009.10.013","article-title":"The capsule drug device: novel approach for drug delivery to the eye","volume":"50","author":"Molokhia","year":"2010","journal-title":"Vis. Res."},{"key":"10.1016\/j.jconrel.2014.04.049_bb0815","first-page":"5395","article-title":"A phase 1 study evaluating the safety and evidence of efficacy of IBI-20089, a triamcinolone intravitreal injection formulated with the VerisomeTM drug delivery technology, in patients with cystoid macular edema","volume":"50","author":"Lim","year":"2009","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.jconrel.2014.04.049_bb0825","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1001\/archopht.1992.01080140044023","article-title":"Sustained-release ganciclovir therapy for treatment of cytomegalovirus retinitis. Use of an intravitreal device","volume":"110","author":"Sanborn","year":"1992","journal-title":"Arch. Ophthalmol."},{"key":"10.1016\/j.jconrel.2014.04.049_bb0830","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1001\/archopht.126.9.1191","article-title":"Treatment of posterior uveitis with a fluocinolone acetonide implant: three-year clinical trial results","volume":"126","author":"Callanan","year":"2008","journal-title":"Arch. Ophthalmol."},{"key":"10.1016\/j.jconrel.2014.04.049_bb0835","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/j.ophtha.2010.12.028","article-title":"Long-term benefit of sustained-delivery fluocinolone acetonide vitreous inserts for diabetic macular edema","volume":"118","author":"Campochiaro","year":"2011","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jconrel.2014.04.049_bb0840","series-title":"Proceedings of ARVO Annual Meeting","article-title":"I-Vation TA: 24-month clinical results of the phase I safety and preliminary efficacy study","author":"Dugel","year":"2009"},{"key":"10.1016\/j.jconrel.2014.04.049_bb0845","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1016\/j.ophtha.2011.05.014","article-title":"Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion twelve-month study results","volume":"118","author":"Haller","year":"2011","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jconrel.2014.04.049_bb0850","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1001\/archophthalmol.2010.339","article-title":"Dexamethasone intravitreal implant for noninfectious intermediate or posterior uveitis","volume":"129","author":"Lowder","year":"2011","journal-title":"Arch. Ophthalmol."},{"key":"10.1016\/j.jconrel.2014.04.049_bb0855","doi-asserted-by":"crossref","first-page":"7484","DOI":"10.1167\/iovs.12-9970","article-title":"Two-year intraocular delivery of ciliary neurotrophic factor by encapsulated cell technology implants in patients with chronic retinal degenerative diseases","volume":"53","author":"Kauper","year":"2012","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.jconrel.2014.04.049_bb0860","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1016\/j.addr.2012.02.005","article-title":"Reservoir-based drug delivery systems utilizing microtechnology","volume":"64","author":"Stevenson","year":"2012","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2014.04.049_bb0865","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3003276","article-title":"First-in-human testing of a wirelessly controlled drug delivery microchip","volume":"4","author":"Farra","year":"2012","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.jconrel.2014.04.049_bb0870","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1177\/0091270010378859","article-title":"Microneedles: a valuable physical enhancer to increase transdermal drug delivery","volume":"51","author":"Escobar-Chavez","year":"2011","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.jconrel.2014.04.049_bb0875","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1111\/j.1600-0846.2005.00107.x","article-title":"Clinical microneedle injection of methyl nicotinate: stratum corneum penetration","volume":"11","author":"Sivamani","year":"2005","journal-title":"Skin Res. Technol."},{"key":"10.1016\/j.jconrel.2014.04.049_bb0880","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1097\/AJP.0b013e318225dbe9","article-title":"Rapid local anesthesia in humans using minimally invasive microneedles","volume":"28","author":"Gupta","year":"2012","journal-title":"Clin. J. Pain"},{"key":"10.1016\/j.jconrel.2014.04.049_bb0885","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1517\/17425240903071029","article-title":"Vesicular carriers for dermal drug delivery","volume":"6","author":"Sinico","year":"2009","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.jconrel.2014.04.049_bb0890","doi-asserted-by":"crossref","first-page":"109","DOI":"10.4155\/tde.10.16","article-title":"Challenges and opportunities in dermal\/transdermal delivery","volume":"1","author":"Paudel","year":"2010","journal-title":"Ther. Deliv."},{"key":"10.1016\/j.jconrel.2014.04.049_bb0895","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1007\/s11095-013-1036-1","article-title":"Diclofenac enables unprecedented week-long microneedle-enhanced delivery of a skin impermeable medication in humans","volume":"30","author":"Brogden","year":"2013","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2014.04.049_bb0900","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1034\/j.1600-0625.2000.009003165.x","article-title":"The 500 Dalton rule for the skin penetration of chemical compounds and drugs","volume":"9","author":"Bos","year":"2000","journal-title":"Exp. Dermatol."},{"key":"10.1016\/j.jconrel.2014.04.049_bb0905","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.addr.2003.10.025","article-title":"Penetration enhancers","volume":"56","author":"Williams","year":"2004","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2014.04.049_bb0910","doi-asserted-by":"crossref","DOI":"10.1517\/17425247.2014.875528","article-title":"Skin permeabilization for transdermal drug delivery: recent advances and future prospects","author":"Schoellhammer","year":"2014","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.jconrel.2014.04.049_bb0915","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.jconrel.2010.02.015","article-title":"Multicomponent chemical enhancer formulations for transdermal drug delivery: more is not always better","volume":"144","author":"Arora","year":"2010","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2014.04.049_bb0920","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1016\/j.yexcr.2010.02.026","article-title":"Mesenchymal stem cell-conditioned medium accelerates skin wound healing: an in vitro study of fibroblast and keratinocyte scratch assays","volume":"316","author":"Walter","year":"2010","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.jconrel.2014.04.049_bb0925","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1111\/j.1468-3083.2006.01629.x","article-title":"Epidermal thickness assessed by optical coherence tomography and routine histology: preliminary results of method comparison","volume":"20","author":"Gambichler","year":"2006","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"10.1016\/j.jconrel.2014.04.049_bb0935","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.jconrel.2011.01.006","article-title":"Ultrasound-mediated transdermal drug delivery: mechanisms, scope, and emerging trends","volume":"152","author":"Polat","year":"2011","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2014.04.049_bb0940","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1517\/17425247.2010.538679","article-title":"Low-frequency sonophoresis: application to the transdermal delivery of macromolecules and hydrophilic drugs","volume":"7","author":"Polat","year":"2010","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.jconrel.2014.04.049_bb0945","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1197\/j.aem.2004.11.019","article-title":"Ultrasound with topical anesthetic rapidly decreases pain of intravenous cannulation","volume":"12","author":"Becker","year":"2005","journal-title":"Acad. Emerg. Med."},{"key":"10.1016\/j.jconrel.2014.04.049_bb0950","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.addr.2003.10.024","article-title":"Low-frequency sonophoresis: a review","volume":"56","author":"Mitragotri","year":"2004","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2014.04.049_bb0955","doi-asserted-by":"crossref","first-page":"13755","DOI":"10.1073\/pnas.2331316100","article-title":"Microfabricated needles for transdermal delivery of macromolecules and nanoparticles: fabrication methods and transport studies","volume":"100","author":"McAllister","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jconrel.2014.04.049_bb0960","first-page":"948","article-title":"Microfabricated microneedles: a novel approach to transdermal drug delivery","volume":"88","author":"Henry","year":"1999","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2014.04.049_bb0965","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.addr.2003.10.023","article-title":"Microneedles for transdermal drug delivery","volume":"56","author":"Prausnitz","year":"2004","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2014.04.049_bb0970","doi-asserted-by":"crossref","first-page":"23","DOI":"10.2174\/1567201052772915","article-title":"Transdermal drug delivery: penetration enhancement techniques","volume":"2","author":"Benson","year":"2005","journal-title":"Curr. Drug Deliv."},{"key":"10.1016\/j.jconrel.2014.04.049_bb0975","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/S0928-0987(01)00167-1","article-title":"Novel mechanisms and devices to enable successful transdermal drug delivery","volume":"14","author":"Barry","year":"2001","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2014.04.049_bb0980","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1159\/000091978","article-title":"Overcoming the stratum corneum: the modulation of skin penetration. A review","volume":"19","author":"Trommer","year":"2006","journal-title":"Skin Pharmacol. Physiol."},{"key":"10.1016\/j.jconrel.2014.04.049_bb0985","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejpb.2010.11.003","article-title":"Potentials of new nanocarriers for dermal and transdermal drug delivery","volume":"77","author":"Neubert","year":"2011","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.jconrel.2014.04.049_bb0990","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ijpharm.2009.06.040","article-title":"Penetration enhancer-containing vesicles (PEVs) as carriers for cutaneous delivery of minoxidil","volume":"380","author":"Mura","year":"2009","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2014.04.049_bb0995","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.ijpharm.2011.03.068","article-title":"Penetration enhancer containing vesicles as carriers for dermal delivery of tretinoin","volume":"412","author":"Manconi","year":"2011","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2014.04.049_bb1000","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.colsurfb.2013.07.014","article-title":"Close-packed vesicles for diclofenac skin delivery and fibroblast targeting","volume":"111C","author":"Manca","year":"2013","journal-title":"Colloids Surf. B: Biointerfaces"},{"key":"10.1016\/j.jconrel.2014.04.049_bb1005","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.ejpb.2006.10.019","article-title":"Nanoparticles\u2014an efficient carrier for drug delivery into the hair follicles","volume":"66","author":"Lademann","year":"2007","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.jconrel.2014.04.049_bb1010","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1111\/j.0022-202X.2004.22717.x","article-title":"Penetration profile of microspheres in follicular targeting of terminal hair follicles","volume":"123","author":"Toll","year":"2004","journal-title":"J. Investig. Dermatol."},{"key":"10.1016\/j.jconrel.2014.04.049_bb1015","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.chemphyslip.2012.01.006","article-title":"Development, characterization and in vivo assessment of effective lipidic nanoparticles for dermal delivery of fluconazole against cutaneous candidiasis","volume":"165","author":"Gupta","year":"2012","journal-title":"Chem. Phys. Lipids"},{"key":"10.1016\/j.jconrel.2014.04.049_bb1020","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1007\/s00420-009-0458-x","article-title":"Nanoparticle dermal absorption and toxicity: a review of the literature","volume":"82","author":"Crosera","year":"2009","journal-title":"Int. Arch. Occup. Environ. Health"}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016836591400282X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016836591400282X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,26]],"date-time":"2024-05-26T09:37:27Z","timestamp":1716716247000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016836591400282X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9]]},"references-count":202,"alternative-id":["S016836591400282X"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2014.04.049","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2014,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Single compartment drug delivery","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2014.04.049","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}